新华医疗收购案终止 标的溢价率高 曾遭董事质疑 |速读公告

Group 1 - Xinhua Medical officially terminated its acquisition plan for Wuhan Zhongzhi Biotechnology Co., Ltd. after more than a year of progress due to the expiration of the agreed delivery deadline [1] - The acquisition was initially announced in December 2024, with Xinhua Medical planning to acquire a 36.19% stake in Zhongzhi Biotechnology for 166 million yuan, aiming to become its controlling shareholder [1] - The termination of the transaction will not adversely affect Xinhua Medical's current operating performance and financial status, as no payments were made prior to the termination [3] Group 2 - The acquisition faced valuation controversies, with Zhongzhi Biotechnology's assessed value reaching 461 million yuan, representing a 428.52% increase over its book value of 87.25 million yuan, raising market concerns [2] - Financial data indicated instability in Zhongzhi Biotechnology's profitability, with revenues of 120 million yuan and net profits of 15.63 million yuan in 2023, but a loss of 11.8 million yuan in the first half of 2025 [2] - The external environment for the in vitro diagnostics industry is changing, with significant policy adjustments expected in 2025, which may further complicate the profitability outlook for companies in this sector [3]